A Phase I Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 and Doxorubicin in Inflammatory Breast Cancer.

Trial Profile

A Phase I Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 and Doxorubicin in Inflammatory Breast Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Mar 2010

At a glance

  • Drugs Semaxanib (Primary) ; Doxorubicin; Tamoxifen
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Mar 2010 Actual end date (Oct 2003) added as reported by ClinicalTrials.gov.
    • 02 Mar 2010 Actual patient number (21) added as reported by ClinicalTrials.gov.
    • 05 Mar 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top